
    
      This is a randomized, double-blind, two treatment, two sequence, placebo-controlled crossover
      study to assess the efficacy and safety of dose Dyanavel XR in reducing signs and symptoms of
      ADHD compared with placebo in pediatric subjects ages 6 to 12 years with ADHD.
    
  